Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.
Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R, Robins P, Tochon-Danguy H, O'Keefe G, Pike KE, Yates P, Szoeke C, Salvado O, Macaulay SL, O'Meara T, Head R, Cobiac L, Savage G, Martins R, Masters CL, Ames D, Villemagne VL. Rowe CC, et al. Among authors: mulligan r. Ann Neurol. 2013 Dec;74(6):905-13. doi: 10.1002/ana.24040. Ann Neurol. 2013. PMID: 24448836 Free article.
Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET.
Mitkovski S, Villemagne VL, Novakovic KE, O'Keefe G, Tochon-Danguy H, Mulligan RS, Dickinson KL, Saunder T, Gregoire MC, Bottlaender M, Dolle F, Rowe CC. Mitkovski S, et al. Nucl Med Biol. 2005 Aug;32(6):585-91. doi: 10.1016/j.nucmedbio.2005.04.013. Nucl Med Biol. 2005. PMID: 16026705
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.
Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL. Rowe CC, et al. Among authors: mulligan r. Lancet Neurol. 2008 Feb;7(2):129-35. doi: 10.1016/S1474-4422(08)70001-2. Epub 2008 Jan 10. Lancet Neurol. 2008. PMID: 18191617
Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.
Ellis JR, Nathan PJ, Villemagne VL, Mulligan RS, Saunder T, Young K, Smith CL, Welch J, Woodward M, Wesnes KA, Savage G, Rowe CC. Ellis JR, et al. Among authors: mulligan rs. Psychopharmacology (Berl). 2009 Jan;202(1-3):79-91. doi: 10.1007/s00213-008-1347-9. Epub 2008 Oct 24. Psychopharmacology (Berl). 2009. PMID: 18949462
In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL. Fodero-Tavoletti MT, et al. Among authors: mulligan rs. Eur J Pharmacol. 2009 Sep 1;617(1-3):54-8. doi: 10.1016/j.ejphar.2009.06.042. Epub 2009 Jul 1. Eur J Pharmacol. 2009. PMID: 19576880
546 results